SEARCH

SEARCH BY CITATION

References

  • Baldassarri S, Bertoni A, Bagarotti A, Sarasso C, Zanfa M, Catani MV et al. (2008). The endocannabinoid 2-arachidonoylglycerol activates human platelets through non-CB1/CB2 receptors. J Thromb Haemost 6: 17721779.
  • Barnes CS, Coker SJ (1995). Failure of nitric oxide donors to alter arrhythmias induced by acute myocardial ischaemia or reperfusion in anaethetized rats. Br J Pharmacol 114: 349356.
  • Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845852.
  • Clark C, Foreman MI, Kane KA, McDonald FM, Parratt JR (1980). Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrrhythmias and for the determination of infarct size. J Pharmacol Methods 3: 357368.
  • Currie S, Rainbow RD, Ewart MA, Kitson S, Herradon-Pliego E, Kane KA et al. (2008). IP3R-mediated Ca2+ release is modulated by anandamide in isolated cardiac nuclei. J Mol Cell Cardiol 45: 804811.
  • Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA (2004). The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 99: 11271130.
  • Durst R, Danenberg H, Gallily R, Beeri R, Mechoulam R, Meir K et al. (2007). Cannabidiol, a non-psychoactive Cannabis constituent protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 293: 36023607.
  • Flores NA, Goulielmos NV, Seghatchian MJ, Sheridan DJ (1994). Myocardial ischaemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects. Cardiovasc Res 28: 16621671.
  • Formukong EA, Evans AT, Evans FJ (1989). The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol 41: 705709.
  • Giudice ED, Rinaldi L, Passarotto M, Facchinetti F, D’Arrigo A, Guiotto A et al. (2007). Cannabidiol, unlike synthetic cannbinoids, triggers activation of RBL-2H3 mast cells. J Leukoc Biol 81: 15121522.
  • Hajrasouliha AR, Tavakoli S, Ghasemi M, Jabehdar-Maralani P, Sadeghipour H, Ebrahimi F et al. (2008). Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur J Pharmacol 579: 246252.
  • Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 82688273.
  • Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX et al. (2007). Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 52: 10791087.
  • Honda T, Kaikita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S et al. (2008). Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol 44: 915926.
  • Humphreys RA, Kane KA, Parratt JR (1998). Lack of involvement of mast cell degranulation in the antiarrhythmic effect of preconditioning in rats. J Cardiovasc Pharmacol 31: 418423.
  • Krylatov AV, Uzhachenko RV, Maslov LN, Bernatskaya NA, Makriyannis A, Mechoulam R et al. (2002). Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: A possible mechanism. Bull Exp Biol Med 133: 144147.
  • Lim SY, Davidson SM, Yellon DM, Smith CC (2009). The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol 104: 781792.
  • Logue SE, Gustafsson AS, Samali A, Gottlieb RA (2005). Ischemia/reperfusion injury at the intersection with cell death. J Moll Cell Cardiol 38: 2133.
  • Maccarrone M, Bari M, Menichelli A, Del Prinipe D, Agro AF (1999). Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett 447: 277282.
  • Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R et al. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 95619566.
  • Mamas MA, Terrar DA (1998). Differential sensitivity to cannabidiol of the two components of delayed rectifier potassium currents in guinea pig isolated ventricular myocytes. Br J Pharmacol 123: 319P.
  • Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (2007). Cannabidiol – recent advances. Chem Biodivers 4: 16781692.
  • Messina A, Knight KR, Dowsing BJ, Zhang B, Phan LH, Hurley JV et al. (2000). Localization of inducible nitric oxide synthase to mast cells during ischemia/reperfusion injury of skeletal muscle. Lab Invest 80: 423431.
  • Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K et al. (2005). Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 36: 10771082.
  • O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA (2009). Time-dependent vascular effects of cannabidiol in the rat aorta. Eur J Pharmacol 612: 6168.
  • Parikh V, Singh M (1997). Resident cardiac mast cells and the cardioprotective effect of ischemic preconditioning in isolated rat heart. J Cardiovasc Pharmacol 30: 149156.
  • Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 153: 199215.
  • Rakhshan F, Day TA, Blakely RD, Barker EL (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292: 960967.
  • Russo EB, Burnett A, Hall B, Parker KK (2005). Agnostic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 10371043.
  • Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B (2009). Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci 29: 20532063.
  • Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 10921101.
  • Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E (2004). Pharmacology of cardiac potassium channels. Cardiovasc Res 62: 933.
  • Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613623.
  • Ugdyzhekova DS, Bernatskaya NA, Stefano JB, Graier VF, Tam SW, Mechoulam R (2001). Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB1 and CB2 receptors. Bull Exp Biol Med 131: 300302.
  • Underdown NJ, Hiley CR, Ford WR (2005). Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 146: 809816.
  • Vannacci A, Giannini L, Passani MB, Di Felice A, Pierpaoli S, Zagli G et al. (2004). The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of guinea pig mast cells: involvement of nitric oxide and eicosanoids. J Pharmacol Exp Ther 311: 256264.
  • Wagner JA, Abesser M, Harvery-White J, Ertl G (2006). 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol 47: 650655.
  • Wainwright CL, Parratt JR, Bigaud M (1988). The effects of PAF antagonists on ischaemia and reperfusion arrhythmias and ischaemia-induced platelet aggregation. Biomed Biochim Acta 47: 224227.
  • Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM et al. (1988). The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion. Cardiovasc Res 22: 447455.
  • Walsh SK, Kane KA, Wainwright CL (2009a). Mast cell degranulation – a mechanism for the anti-arrhythmic effect of endothelin-1? Br J Pharmacol 157: 716723.
  • Walsh SK, Kane KA, Wainwright CL (2009b). Mast cells, peptides and cardioprotection – an unlikely marriage? Auton Autacoid Pharmacol 29: 7384.
  • Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R et al. (2008). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54: 244249.